topic

1509-D Dysgerminoma ovarian germ cell tumours present high expressions of PDL-1 that associated with high tumour infiltrating lymphocytes and good patient prognosis
Kholoud Alwosaibai

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1857; DOI: 10.1136/jitc-2023-SITC2023.1509-D
1509-F TFEB activation in mediastinal lymph nodes: a potential modulator of immune response in NSCLC
Ines Mota, Laura Santambrogio

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1858; DOI: 10.1136/jitc-2023-SITC2023.1509-F
1509-G M2 macrophage-derived exosomal microRNA-21–3p promotes colorectal cancer progression via mediating FAM46C
Hye Yeon Jung, Seung Ja Oh

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1859; DOI: 10.1136/jitc-2023-SITC2023.1509-G
1509-H Quantitative assessment of the tumor microenvironment using the Aurora™ 3D Spatial Biology Platform
Caleb Stoltzfus, Alexandra Alvarsson, Anna DeWitt, Jasmine Wilson, Nathan Grant, David Simmons, Brandy Olin, Bonnie Phillips, Laura A Dillon, Guy Travis Clifton, Nicholas Reder

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1860; DOI: 10.1136/jitc-2023-SITC2023.1509-H
Author index
Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1861-A1866; DOI: 10.1136/jitc-2023-SITC2023.authorindexlba
Subject index
Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1867; DOI: 10.1136/jitc-2023-SITC2023.subjectindexlba
1541 Stability of the gut microbiota during anti-pd1 immunotherapy defines complete response in melanoma patients
Angeli DG Macandog, Carlotta Catozzi, Mariaelena Capone, Amir Nabinejad, Gabriele Madonna, Massimo Barberis, Pier Ferrucci, Nicola Segata, Luigi Buonaguro, Emilia Cocorocchio, Paolo A Ascierto, Teresa Manzo, Luigi Nezi

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1766; DOI: 10.1136/jitc-2023-SITC2023.1541
Correction: CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression
Journal for ImmunoTherapy of Cancer Dec 2023, 11 (12) e007398corr1; DOI: 10.1136/jitc-2023-007398corr1
Correction: Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis
Journal for ImmunoTherapy of Cancer Dec 2023, 11 (12) e006982corr1; DOI: 10.1136/jitc-2023-006982corr1
Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer
Douglas G McNeel, Hamid Emamekhoo, Jens C Eickhoff, Christos E Kyriakopoulos, Ellen Wargowski, Tommaso P Tonelli, Laura E Johnson, Glenn Liu

Journal for ImmunoTherapy of Cancer Dec 2023, 11 (12) e008067; DOI: 10.1136/jitc-2023-008067

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages